Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: Closed-End Fund
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: U.S.

Tekla Life Sciences Investors

+ Add to Watchlist

HQL:US

26.8200 USD 0.0200 0.07%

As of 20:04:02 ET on 05/04/2015.

Snapshot for Tekla Life Sciences Investors (HQL)

Open: 26.9000 High - Low: 27.2499 - 26.8100 Primary Exchange: New York
Volume: 49,565 52-Week Range: 19.2373 - 29.1500 Beta vs NBI: 0.8551

ETF Chart for HQL

No chart data available.
  • HQL:US 26.8200
  • 1D
  • 1M
  • 1Y
26.8000
Interactive HQL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for HQL

Tekla Life Sciences Investors is a diversified, closed-end management investment company incorporated in the USA. The Fund's objective is long-term capital appreciation. The Fund invests mainly in securities of life sciences companies and primarily in securities of public and private companies that are believed to have significant potential for above-average growth.

Inception Date: 1992-05-08 Telephone: 1-617-772-8500
Managers: DANIEL R OMSTEAD "DAN"
Web Site: www.teklacap.com

Fundamentals for HQL

NAV (on 2015-05-04) 27.3700
Assets (M) (on 2015-05-04) 528.8436
Shares out (M) 19.32
Market Cap (M) 518.19
% Premium -2.01
Average 52-Week % Premium -1.4846
Fund Leveraged N

Dividends for HQL

Dividend Type Income
Dividend Frequency Quarter
Last Dividend Net (on 2015-02-26) 0.5000
Dividend Yield (ttm) 6.85%

Performance for HQL

1-Month -0.81% 1-Year +41.84%
3-Month +3.82% 3-Year +35.36%
Year To Date +9.70% 5-Year +32.51%
Expense Ratio 1.32

Top Fund Holdings for HQL

Filing Date: 09/30/2014
Name Position Value % of Total
Gilead Sciences Inc 563,820 60,018,639 13.515%
Celgene Corp 436,322 41,354,599 9.312%
Vertex Pharmaceuticals Inc 206,557 23,198,417 5.224%
Alexion Pharmaceuticals Inc 127,799 21,191,630 4.772%
Regeneron Pharmaceuticals Inc 54,522 19,656,271 4.426%
Amgen Inc 136,594 19,185,993 4.320%
Biogen Inc 54,182 17,923,947 4.036%
Incyte Corp 259,915 12,748,831 2.871%
Actavis plc 46,815 11,295,523 2.544%
Shire PLC 37,379 9,683,030 2.180%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil